|
UNITED STATES |
SECURITIES AND EXCHANGE COMMISSION |
WASHINGTON, D.C. 20549 |
|
|
|
FORM 8-K |
|
CURRENT REPORT |
Pursuant to Section 13 or 15(d) of the |
Securities Exchange Act of 1934 |
| |
Date of Report (Date of earliest event reported) | November 10, 2010 |
|
|
ENZON PHARMACEUTICALS, INC. |
|
(Exact name of registrant as specified in its charter) |
| | |
Delaware | 0-12957 | 22-2372868 |
|
(State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Identification No.) |
| | | |
| 685 Route 202/206, Bridgewater, New Jersey | 08807 | |
|
| (Address of principal executive offices) | (Zip Code) | |
| | | |
Registrant’s telephone number, including area code | (908) 541-8600 | |
|
| |
|
(Former name or former address, if changed since last report) | | |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
o | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
o | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
| |
o | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.05. Amendment to Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.
On November 10, 2010, the Board of Directors of Enzon Pharmaceuticals, Inc. (the “Enzon”) approved amendments to Enzon’s Code of Conduct (the “Code of Conduct”) that were administrative in nature and designed to reflect Enzon’s current business operations. The full text of the Code of Conduct, as amended, is available on Enzon’s websiteat www.enzon.com.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 12, 2010
| | |
| By: | /s/ Andrew Rackear |
| |
|
| | Andrew Rackear |
| | Vice President & General Counsel |
